APRIL CAR-T cells 비교 | 바이오정보모아

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview MoA Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 1 APRIL CAR-T cells (APRIL CAR-T cells) Yake Biotechnology Ltd.·FRα 4 trials

Overview Program	APRIL CAR-T cells
Overview Company	Yake Biotechnology Ltd.
Overview Modality	CGT
Overview Target	FRα
Overview Indication	Multiple Myeloma in Relapse; Multiple Myeloma, Refractory
Overview Phase	PHASE_1
Overview Status	RECRUITING
Overview Content status	Standard Database
Overview Data Confidence	Editorial scope · structured catalog
Overview Development Signal	Development Signal · Watch
Overview Approval status	Investigational

MoA Mechanism	CAR T-cell-mediated binding and killing of myeloma cells which might contribute to the efficacy of
MoA Biomarker	BCMA but with a much low

Clinical Program phase	PHASE_1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview MoA Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 1 APRIL CAR-T cells (APRIL CAR-T cells) Yake Biotechnology Ltd.·FRα 4 trials

Overview Program	APRIL CAR-T cells
Overview Company	Yake Biotechnology Ltd.
Overview Modality	CGT
Overview Target	FRα
Overview Indication	Multiple Myeloma in Relapse; Multiple Myeloma, Refractory
Overview Phase	PHASE_1
Overview Status	RECRUITING
Overview Content status	Standard Database
Overview Data Confidence	Editorial scope · structured catalog
Overview Development Signal	Development Signal · Watch
Overview Approval status	Investigational

MoA Mechanism	CAR T-cell-mediated binding and killing of myeloma cells which might contribute to the efficacy of
MoA Biomarker	BCMA but with a much low

Clinical Program phase	PHASE_1

APRIL CAR-T cells 비교 | 바이오정보모아